

### Immune-based therapies for hepatocellular carcinoma | ...

<https://www.nature.com/articles/s41388-020-1249-9>

Mar 10, 2020 · Regulatory T-cells (T-reg) are CD4+/CD25+/FOXP3+immune-suppressive T-cells whose accumulation in HCC is associated with disease progression and reduced survival [31, 57].

Cited by: 26

Author: David J. Pinato, Nadia Guerra, Petros Fe...

Publish Year: 2020

### Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26106627>

May 28, 2015 · In both autoimmune liver disease and chronic viral hepatitis, the injury results from an immune-mediated cytotoxic T cell response to liver cells. As such, it is not surprising that CD4 + regulatory T cells, a key regulatory population of T cells able to curb immune responses, could be involved in both autoimmune hepatitis and chronic viral ...

Cited by: 14

Author: Pascal Lapierre, Alain Lamarre

Publish Year: 2015

### Perioperative dynamic alterations in peripheral regulatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292477>

Jan 25, 2012 · Background. Regulatory T cells (Tregs) are a subpopulation of CD4 + and CD8 + T cells with immune suppressive function. In cancer patients especially patients with hepatocellular carcinoma (HCC), Tregs contribute to the dampening of the antitumor immune response [1,2].Patients undergoing hepatic resection for HCC with prominent Treg infiltration showed increased recurrence and worse ...

Cited by: 24

Author: Tianxiang Chen, Dongli Song, Zhihui Min,...

Publish Year: 2012

### Regulatory T cells and IL-17+ T helper cells enhanced in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538083>

Jun 15, 2015 · In recent years, regulatory T (Treg) cells and IL-17+ T helper (Th17) cells played an important role in autoimmune diseases and many studies proved that the expression of Treg and Th17 cells were changed in the patients with CHB, HBV-LC or HBV-HCC [11-13], but the systematic study of the change in different stages of chronic HBV infection were ...

Cited by: 9

Author: Hao Feng, Jie Yin, Ya-Ping Han, Xiao-Yin...

Publish Year: 2015

59,000 Results

Any time ▾

### Immune-based therapies for hepatocellular carcinoma | Oncogene

<https://www.nature.com/articles/s41388-020-1249-9>

Mar 10, 2020 · **Regulatory T-cells** (T-reg) are CD4+/CD25+/FOXP3+immune-suppressive T-cells whose accumulation in HCC is associated with disease progression and reduced survival [31, 57].

Cited by: 29

Author: David J. Pinato, Nadia Guerra, Petros Fess...

Publish Year: 2020

### The immunology of hepatocellular carcinoma - Nature

<https://www.nature.com/articles/s41590-018-0044-z>

Jan 29, 2018 · Spear, T. T. et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated **hepatocellular carcinoma** tumors. Cancer Immunol. Immunother. 65, 293–304 (2016).

Cited by: 302

Author: Marc Ringelhan, Dominik Pfister, Tracy O'C...

Publish Year: 2018

### FOXP3 gene polymorphism is associated with hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718693>

A previous study showed that the local tumor **immune microenvironment** plays an important role in cancer suppression and promotion and that one of the main factors leading to tumor **immune tolerance** in the local tumor **microenvironment** is the influence of CD4+/CD25+/FOXP3+ regulatory T cells (Tregs) .

Cited by: 26

Author: YanHui Chen, HengHui Zhang, WeiJia Liao, ...

Publish Year: 2013

### Multidimensional analyses reveal distinct immune ...

<https://gut.bmj.com/content/68/5/916> ▾

May 01, 2019 · Results: In-depth interrogation of the immune landscapes showed that regulatory T cells

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 63873

Manuscript Type: REVIEW

**Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment**

Regulatory T cells in liver diseases

**Abstract**

More than 90% of cases of *hepatocellular carcinoma* (HCC) occurs in *patients* with *cirrhosis*, of which *hepatitis B virus* (HBV) and *hepatitis C virus* (HCV) are the leading causes, while the tumor less frequently arises in autoimmune liver diseases.

Advances in understanding tumor immunity have led to a major shift in the treatment of HCC, with the emergence of immunotherapy where therapeutic agents are used to target immune cells rather than cancer cells. Regulatory T cells (Tregs) are the most abundant suppressive cells in the tumor microenvironment and their presence has been

Match Overview

1	Crossref 170 words T. Alissafi, A. Hatzioannou, A.I. Legaki, A. Varveri, Panayot is Verginis. "Balancing cancer immunotherapy and immu...	4%
2	Crossref 113 words Eleonora Timperi, Vincenzo Barnaba. "Chapter 3 Viral Hi... astides, Inflammation and Tumour Microenvironment", Spri	3%
3	Crossref 99 words Eleonora De Martin, Jean-Marie Michot, Olivier Rosmorduc, Catherine Quetier, Didier Samuel. "Liver toxicity as a f...	3%
4	Internet 79 words crawled on 10-Apr-2020 <a href="http://www.nature.com">www.nature.com</a>	2%
5	Internet 46 words crawled on 24-Nov-2017 <a href="http://www.dovepress.com">www.dovepress.com</a>	1%
6	Internet 39 words crawled on 30-Sep-2019 <a href="http://journals.sagepub.com">journals.sagepub.com</a>	1%
7	Internet 37 words crawled on 08-Jul-2017 <a href="http://jci.org">jci.org</a>	1%
8	Crossref 35 words David J. Pinato, Nadia Guerra, Petros Fessas, Ravindhi I... urphy et al. "Immune-based therapies for hepatocellular ca	1%
9	Crossref 30 words	10%

国内版 国际版

Hepatocellular carcinoma in viral and autoimmune liver diseases: Rc



ALL IMAGES VIDEOS

55,800 Results

Any time ▾

### The immunology of hepatocellular carcinoma - Nature

<https://www.nature.com/articles/s41590-018-0044-z>

Jan 29, 2018 · Spear, T. T. et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol. Immunother. 65 , 293–304 (2016).

Cited by: 302

Author: Marc Ringelhan, Dominik Pfister, Tracy O'...

Publish Year: 2018

### Immune-based therapies for hepatocellular carcinoma | ...

<https://www.nature.com/articles/s41388-020-1249-9>

Mar 10, 2020 · Regulatory T-cells (T-reg) are CD4+/CD25+/FOXP3+immune-suppressive T-cells whose accumulation in HCC is associated with disease progression and reduced survival [31, 57].

Cited by: 29

Author: David J. Pinato, Nadia Guerra, Petros Fe...

Publish Year: 2020

### Immunotherapy in hepatocellular carcinoma: the complex ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0749-z> ▾

Oct 18, 2019 · Introduction. Hepatocellular carcinoma (HCC) is a disease with both a grim prognosis and rising incidence. The most up to date estimates demonstrate a median overall survival of 9 months for all stages of untreated HCC, a number that worsens with increasing Barcelona Clinic Liver Cancer (BCLC) stage [1]. In the world, liver cancer is the third leading cause of cancer mortality while in the ...

Cited by: 24

Author: Bridget P. Keenan, Lawrence Fong, Robin...

Publish Year: 2019

### In Situ Vaccination as a Strategy to Modulate the Immune ...

<https://www.frontiersin.org/articles/10.3389/fimmu.2021.650486> ▾

Hepatocellular Carcinoma (HCC) is a highly prevalent malignancy that develops in patients with chronic liver diseases and dysregulated systemic and hepatic immunity. The tumor microenvironment (TME) contains tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAF), regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) and is central to mediating immune evasion ...

### FOXP3 gene polymorphism is associated with hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740602>